Description of Medical ServiceOncotype DX® is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.
Description of Medical ConditionOutside Australia, Oncotype DX® is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative
Previous Application Number1342.3
PICO ConfirmationAs per application 1342
Public Summary DocumentPublic Summary Document (PDF 445 KB)
Public Summary Document (Word 104 KB)